Nature Medicine

Newly defined biomarker may accelerate clinical trials for vaccines to prevent HIV-1 infection – the Antibody Mediated Prevention (AMP) trials

A new biomarker appears to be an effective surrogate endpoint to reliably predict the ability of broadly neutralizing monoclonal antibodies to prevent acquisition of HIV-1. Broadly neutralizing antibodies (bnAbs) are defined by their ability to neutralize multiple genetically distinct viral strains.
Go to the profile of Elena E. Giorgi
Aug 25, 2022